AlT4™
TLR4 on Alum
The TLR4 agonist is absorbed onto aluminum hydroxide (alum) particles. These alum particles consist of nanometer crystals that assemble into aggregates of several micrometers and provide a stable particulate formulation for the sustained release of adjuvant. In vivo data indicate that TLR4-alum directs the quality of the immune response to a balanced Th1/Th2 response, whereas alum alone induces a strict Th2 response. The product potential of a TLR4-alum formulation is very promising given that the FDA approved GSK’s cervical cancer vaccine Cervarix® containing a very similar MPL-alum adjuvant formulation.
Sold in a vial of 000 mil.
Research-grade only.
Contact us for a Quote for Bulk Orders
$250.00
Recently Viewed Items
You haven't viewed at any of the products yet.